Slow-growing melanomas lose structure, vary color with time

Share this article:
Slow-Growing Melanomas Lose Structure, Vary Color With Time
Slow-Growing Melanomas Lose Structure, Vary Color With Time

(HealthDay News) -- The diameter of most slow-growing melanomas (SGMs) changes very little over time, but the lesions can become more disorganized, less structured, and change or develop new colors, according to a study published in the June issue of the British Journal of Dermatology.

Vitaly Terushkin, M.D., of Memorial Sloan-Kettering Cancer Center in New York City, and colleagues retrospectively assessed a dermoscopic image dataset of 92 SGMs from 15 pigmented lesion clinics that were sequentially followed for one year or more. Changes in global pattern, organization, color, structure, and size were evaluated at baseline and follow-up.

The researchers found that, on follow-up, the dermoscopic pattern of the melanomas became more homogeneous and less reticular; the melanomas had more frequent disorganization of pattern; there was a reduction in the prominence of dermoscopic structure of pigmented network and a simultaneous increase in the prominence of areas with no structure; and they developed more melanoma-specific dermoscopic structures. Color changes included a decrease in light brown and increases in the prominence of dark brown and the frequency of new colors (red, white, grey, blue, and black). Seventy-five percent of lesions grew by less than 2 mm or remained the same size; an increase in size correlated with the total number of colors and structures.

"Physicians should pay particular attention to melanocytic lesions that, over time, become more disorganized, reveal a loss of network in favor of structureless areas, develop a negative network, and exhibit new colors such as dark brown, black, grey, blue, red, and white; in addition, one should not rely solely on change in size," the authors write.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Chronic prostate inflammation associated with prostate cancer

Chronic prostate inflammation associated with prostate cancer

The presence of chronic inflammation in benign prostate tissue samples is associated with prostate cancer, especially high-grade disease, according to a study.

Statins may lower progression risk for renal cancer

Statins may lower progression risk for renal cancer

Use of statins is associated with a reduced risk of progression of localized renal cell carcinoma, according to research.

Cyramza approved by FDA for stomach cancer

Cyramza approved by FDA for stomach cancer

Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.